Editas Medicine (EDIT) Net Cash Flow Growth (3y) (2018 - 2025)
Editas Medicine (EDIT) Net Cash Flow Growth (3y) (2018 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -50.33% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 38.47% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 33.37% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -29.82% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Editas Medicine | 245.95 Mn | 99.30 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -14.41% |
| Jun 30, 2025 | 84.65% |
| Mar 31, 2025 | -0.96% |
| Dec 31, 2024 | 38.10% |
| Sep 30, 2024 | 33.94% |
| Jun 30, 2024 | 34.57% |
| Mar 31, 2024 | -31.09% |
| Dec 31, 2023 | 31.88% |
| Sep 30, 2023 | 12.48% |
| Jun 30, 2023 | -28.81% |
| Mar 31, 2023 | -39.80% |
| Dec 31, 2022 | -36.06% |
| Sep 30, 2022 | 33.71% |
| Jun 30, 2022 | -40.74% |
| Mar 31, 2022 | -31.75% |
| Dec 31, 2021 | -64.39% |
| Sep 30, 2021 | -56.79% |
| Jun 30, 2021 | 41.59% |
| Mar 31, 2021 | 44.70% |
| Sep 30, 2020 | -27.81% |